news

 • An international study, with the participation of over 500,000 women, reveals that women who are married when diagnosed with breast cancer have a better chance of survival, regardless of tumor characteristics

• The study, in which the Vall d´Hebron University Hospital and the Vall d’Hebron Institute of Oncology (VHIO) have participated, will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)

A special study visit was jointly organized by the Centre of Genomic Regulation (CRG) and the European Molecular Biology Laboratory (EMBL) as partners of the EU CommHERE Communicating European Health Research Network, in collaboration with the European Union of Science Journalists’ Associations (EUSJA)
 

This year´s annual Fero Foundation (Fundación de Investigación Oncológica) Grant for Translational Research, amounting to 70,000 EUR was presented Monday 12 May, to Sandra Peiró for a two year research project aimed at determining the three-dimensional structure of the tumor cell genome with emphasis on tumor progression and metastatis.

• The Bioinformatics Barcelona (BIB) platform, a joint initiative of the Government of Catalonia and the Welfare Projects Division of the “la Caixa” Foundation, comprises more than 40 organisations including universities, research centers of excellence, and companies.

• Bioinformatics Barcelona (BIB) aims to become an international reference in promoting multidisciplinary research, training, and technology transfer in bioinformatics.

Barcelona, April 11, 2014. Preclinical, translational and clinical researchers and physician-scientists from the Vall d’Hebron Institute of Oncology (VHIO) attended…

Published today in The New England Journal of Medicine, a multi-center phase I clinical study conducted across 11 countries, co-authored by Enriqueta Felip, Principal Investigator of VHIO´s Thoracic Tumors Group, represents an important step forward in the treatment of patients with ALK-rearranged lung cancer.

PHILADELPHIA — The members of the American Association for Cancer Research (AACR) have elected José Baselga, M.D., Ph.D., physician-in-chief at Memorial Sloan Kettering Cancer Center in New York, N.Y., as their president-elect for 2014-2015. Baselga is an internationally recognized physician-scientist whose research focuses on the clinical development of novel molecularly targeted agents for the treatment of cancer, particularly breast cancer.

An international study published in The New England Journal of Medicine, in which the Vall d’Hebron University Hospital and Vall d´Hebron Institute of Oncology (VHIO) have participated, shows that administering bevacizumab in combination with chemotherapy in the first-line treatment of patients with recurrent and/or metastatic cervical cancer improves survival rates and reduces risk of death from this disease by 30%.

Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…

An interview with Ana Vivancos, Principal Investigator of VHIO´s Cancer Genomics Group “We are one of the few groups in…